These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 30630778)

  • 1. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
    von Groote-Bidlingmaier F; Patientia R; Sanchez E; Balanag V; Ticona E; Segura P; Cadena E; Yu C; Cirule A; Lizarbe V; Davidaviciene E; Domente L; Variava E; Caoili J; Danilovits M; Bielskiene V; Staples S; Hittel N; Petersen C; Wells C; Hafkin J; Geiter LJ; Gupta R
    Lancet Respir Med; 2019 Mar; 7(3):249-259. PubMed ID: 30630778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delamanid for multidrug-resistant pulmonary tuberculosis.
    Gler MT; Skripconoka V; Sanchez-Garavito E; Xiao H; Cabrera-Rivero JL; Vargas-Vasquez DE; Gao M; Awad M; Park SK; Shim TS; Suh GY; Danilovits M; Ogata H; Kurve A; Chang J; Suzuki K; Tupasi T; Koh WJ; Seaworth B; Geiter LJ; Wells CD
    N Engl J Med; 2012 Jun; 366(23):2151-60. PubMed ID: 22670901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Cevik M; Thompson LC; Upton C; Rolla VC; Malahleha M; Mmbaga B; Ngubane N; Abu Bakar Z; Rassool M; Variava E; Dawson R; Staples S; Lalloo U; Louw C; Conradie F; Eristavi M; Samoilova A; Skornyakov SN; Ntinginya NE; Haraka F; Praygod G; Mayanja-Kizza H; Caoili J; Balanag V; Dalcolmo MP; McHugh T; Hunt R; Solanki P; Bateson A; Crook AM; Fabiane S; Timm J; Sun E; Spigelman M; Sloan DJ; Gillespie SH;
    Lancet Infect Dis; 2024 Sep; 24(9):1003-1014. PubMed ID: 38768617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
    Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
    Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
    Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea.
    Mok J; Kang H; Hwang SH; Park JS; Kang B; Lee T; Koh WJ; Yim JJ; Jeon D
    J Antimicrob Chemother; 2018 Feb; 73(2):503-508. PubMed ID: 29069496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy.
    Dawson R; Diacon AH; Takuva S; Liu Y; Zheng B; Karwe V; Hafkin J
    Trials; 2024 Jan; 25(1):70. PubMed ID: 38243296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
    Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profile of delamanid for the treatment of multidrug-resistant tuberculosis.
    Szumowski JD; Lynch JB
    Drug Des Devel Ther; 2015; 9():677-82. PubMed ID: 25678771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.
    Blair HA; Scott LJ
    Drugs; 2015 Jan; 75(1):91-100. PubMed ID: 25404020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial.
    Lee JK; Lee JY; Kim DK; Yoon HI; Jeong I; Heo EY; Park YS; Jo YS; Lee JH; Park SS; Park JS; Kim J; Lee SM; Joh JS; Lee CH; Lee J; Choi SM; Park JH; Lee SH; Cho YJ; Lee YJ; Kim SJ; Kwak N; Hwang YR; Kim H; Ki J; Lim JN; Choi HS; Lee M; Song T; Kim HS; Han J; Ahn H; Hahn S; Yim JJ
    Lancet Infect Dis; 2019 Jan; 19(1):46-55. PubMed ID: 30477961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.
    Wallis RS; Ginindza S; Beattie T; Arjun N; Likoti M; Edward VA; Rassool M; Ahmed K; Fielding K; Ahidjo BA; Vangu MDT; Churchyard G
    Lancet Respir Med; 2021 Aug; 9(8):897-908. PubMed ID: 33740465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
    Conde MB; Efron A; Loredo C; De Souza GR; Graça NP; Cezar MC; Ram M; Chaudhary MA; Bishai WR; Kritski AL; Chaisson RE
    Lancet; 2009 Apr; 373(9670):1183-9. PubMed ID: 19345831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug-resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia.
    Soedarsono S; Mertaniasih NM; Kusmiati T; Permatasari A; Subay S; Adiono SH
    Int J Mycobacteriol; 2024 Apr; 13(2):140-146. PubMed ID: 38916383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.
    Li Y; Sun F; Zhang W
    Drug Dev Res; 2019 Feb; 80(1):98-105. PubMed ID: 30548290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug-resistant tuberculosis and culture conversion with bedaquiline.
    Diacon AH; Pym A; Grobusch MP; de los Rios JM; Gotuzzo E; Vasilyeva I; Leimane V; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; De Paepe E; van Heeswijk RP; Dannemann B;
    N Engl J Med; 2014 Aug; 371(8):723-32. PubMed ID: 25140958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.
    Mok J; Lee M; Kim DK; Kim JS; Jhun BW; Jo KW; Jeon D; Lee T; Lee JY; Park JS; Lee SH; Kang YA; Lee JK; Kwak N; Ahn JH; Shim TS; Kim SY; Kim S; Kim K; Seok KH; Yoon S; Kim YR; Kim J; Yim D; Hahn S; Cho SN; Yim JJ;
    Lancet; 2022 Oct; 400(10362):1522-1530. PubMed ID: 36522208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.